164 related articles for article (PubMed ID: 35970525)
1. A Retrospective Analysis of Outcome in Melanoma Differentiation-Associated Gene 5-Related Interstitial Lung Disease Treated with Tofacitinib or Tacrolimus.
Fan L; Lyu W; Liu H; Jiang H; Chen L; Liu Y; Zhuang Y; Huang M; Cao M; Cai H; Xiao Y; Dai J
J Rheumatol; 2022 Dec; 49(12):1356-1364. PubMed ID: 35970525
[TBL] [Abstract][Full Text] [Related]
2. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
3. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
[TBL] [Abstract][Full Text] [Related]
4. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
Ishikawa Y; Kasuya T; Fujiwara M; Kita Y
Medicine (Baltimore); 2020 Sep; 99(37):e21943. PubMed ID: 32925726
[TBL] [Abstract][Full Text] [Related]
6. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
[TBL] [Abstract][Full Text] [Related]
7. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
Hama S; Akiyama M; Higashida-Konishi M; Oshige T; Takei H; Izumi K; Oshima H; Okano Y
Mod Rheumatol Case Rep; 2023 Jan; 7(1):92-95. PubMed ID: 35680682
[TBL] [Abstract][Full Text] [Related]
9. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
10. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
[TBL] [Abstract][Full Text] [Related]
14. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
Ge Y; Li S; Tian X; He L; Lu X; Wang G
Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
16. Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study.
Yamaguchi K; Nakajima T; Yamaguchi A; Itai M; Onuki Y; Shin Y; Uno S; Muto S; Kouno S; Yatomi M; Aoki-Saito H; Hara K; Endo Y; Motegi SI; Muro Y; Nakasatomi M; Sakairi T; Hiromura K; Katsumata N; Hirasawa H; Tsushima Y; Maeno T
Clin Rheumatol; 2022 May; 41(5):1473-1481. PubMed ID: 35034225
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
Kurasawa K; Arai S; Namiki Y; Tanaka A; Takamura Y; Owada T; Arima M; Maezawa R
Rheumatology (Oxford); 2018 Dec; 57(12):2114-2119. PubMed ID: 30060040
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of fungal infection in anti-melanoma differentiation-associated gene 5 antibody-positive associated interstitial lung disease.
Zhou W; Chen H; Ji T; Chen R; Xu Q; Chen L; Cao M; Cai H; Dai J
Clin Rheumatol; 2024 Apr; 43(4):1381-1392. PubMed ID: 38345696
[TBL] [Abstract][Full Text] [Related]
20. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
